Piramal Pharma Limited has released its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, prepared by the independent firm N L Bhatia & Associates, confirms the company’s adherence to statutory requirements, corporate governance standards, and regulatory guidelines. The findings demonstrate the firm’s commitment to maintaining robust compliance systems, ensuring transparent management practices, and upholding high ethical standards in its corporate operations throughout the review period.
Commitment to Corporate Governance
As part of its regulatory disclosures, Piramal Pharma Limited has made public the findings of its annual audit concerning corporate compliance. The audit, conducted by N L Bhatia & Associates, focused on evaluating the internal systems, records, and disclosures maintained by the company throughout the fiscal year 2025-26. The assessment validates that the company has effectively implemented the necessary frameworks to meet its statutory obligations.
Compliance and Oversight Highlights
The comprehensive review confirms that the company has maintained full compliance with key operational standards. Key areas reviewed included Board performance evaluations, Related Party Transactions, and the preservation of documents. The audit noted that all policies are appropriately reviewed, timely updated, and aligned with current industry standards. Furthermore, the company continues to maintain a functional and transparent website for investor information.
Audit Findings
The report underscores that there were no instances of disqualification among the company’s directors under the Companies Act, 2013. Additionally, the company has successfully met the requirements regarding the identification and disclosure of material subsidiaries. The independent auditors concluded that the company has upheld strong governance practices, ensuring that all required disclosures were made within the prescribed time limits, further solidifying its reputation for operational integrity.
Source: BSE
